Servico de Saude da Regiao Autonoma Da Madeira EPERAM

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia1 trial
• Chronic kidney disease1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Parkinson disease1 trial
• Polycystic kidney disease1 trial
• Primary biliary cholangitis1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Recruiting3 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials

Lead sponsor

• Boehringer Ingelheim1 trial
• Calico Life Sciences LLC1 trial
• Fundacion PETHEMA1 trial
• Hoffmann-La Roche1 trial
• Ipsen1 trial
• and 2 more

Running trials

• Recruiting

  A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy

  2025-523238-17-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

  2025-521562-95-00· Phase 3· Mabxience Research S.L.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting